Delivery Order SPE2DB22D1202-SPE2DB25FVGE7
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,188.98 on July 22, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 23, 2025, and performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This...
- The Defense Logistics Agency awarded a $1,270.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The delivery...
- The Defense Logistics Agency awarded a $5,045.87 delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies on July 18, 2025, with completion scheduled for July 21, 2025. This firm fixed-price contract, which is non-set-aside and competitively awarded, represents a small-value transaction within AmerisourceBergen's broader portfolio of pharmaceutical and medical supply deliveries to federal healthcare systems. The auto-injector product falls within the...
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- This delivery order, awarded July 28, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides Xyosted 100 mg/0.5 mL auto-injector pharmaceutical supplies with a ceiling value of $1,092.55. The contract utilizes firm fixed pricing and is scheduled for completion by July 29, 2025. As a non-set-aside, competitively awarded delivery order, this award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $1,681.90 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector pharmaceutical product. The contract was awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, utilizing firm fixed-price pricing with no set-aside designation. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a competitive award under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $1,524.90 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector supplies on July 18, 2025, with completion targeted for July 21, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award based on capability. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical delivery order. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,646.02 to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units on July 25, 2025, with completion scheduled for July 28, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitive award under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xyosted is a...
- The Defense Logistics Agency awarded a $3,155.07 delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector medication, with performance scheduled for completion by July 22, 2025. This non-competitive delivery order represents a firm fixed price contract executed on July 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $1,721.26 to AmerisourceBergen Drug Corp for 0.5 mL of Xyosted 100 mg/0.5 mL auto-injector on July 24, 2025, with an ultimate completion date of July 25, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVGE7Delivery Order
The Defense Logistics Agency awarded a $2,150.75 delivery order to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 ml auto-injector units. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government, supporting the Defense Logistics Agency's medical supply chain operations. This delivery order is issued under AmerisourceBergen's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. AmerisourceBergen serves as a prime pharmaceutical vendor for the Defense Health Agency and other military healthcare systems, supplying a broad portfolio of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The Xyosted auto-injector delivery supports the company's critical role in providing pharmaceutical products to military medical supply chains globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 8/1/25 |